213 related articles for article (PubMed ID: 33096010)
1. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
Sabha M; Siaton BC; Hochberg MC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
[No Abstract] [Full Text] [Related]
2. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Clauw D; Jones M; Bergfeld J; Swearingen CJ; DiFrancesco A; Simsek I; Tambiah J; Hochberg MC
Arthritis Rheumatol; 2020 Oct; 72(10):1694-1706. PubMed ID: 32432388
[TBL] [Abstract][Full Text] [Related]
3. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
Yazici Y; McAlindon TE; Fleischmann R; Gibofsky A; Lane NE; Kivitz AJ; Skrepnik N; Armas E; Swearingen CJ; DiFrancesco A; Tambiah JRS; Hood J; Hochberg MC
Osteoarthritis Cartilage; 2017 Oct; 25(10):1598-1606. PubMed ID: 28711582
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.
Deshmukh V; Hu H; Barroga C; Bossard C; Kc S; Dellamary L; Stewart J; Chiu K; Ibanez M; Pedraza M; Seo T; Do L; Cho S; Cahiwat J; Tam B; Tambiah JRS; Hood J; Lane NE; Yazici Y
Osteoarthritis Cartilage; 2018 Jan; 26(1):18-27. PubMed ID: 28888902
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Lattermann C; Skrepnik N; Swearingen CJ; Simsek I; Ghandehari H; DiFrancesco A; Gibbs J; Tambiah JRS; Hochberg MC
Osteoarthritis Cartilage; 2021 May; 29(5):654-666. PubMed ID: 33588087
[TBL] [Abstract][Full Text] [Related]
7. Wnt signaling: a promising target for osteoarthritis therapy.
Wang Y; Fan X; Xing L; Tian F
Cell Commun Signal; 2019 Aug; 17(1):97. PubMed ID: 31420042
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis.
Oo WM; Liu X; Hunter DJ
Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):1021-1032. PubMed ID: 31709838
[No Abstract] [Full Text] [Related]
9. A novel disease-modifying osteoarthritis drug candidate targeting Runx1.
Yano F; Hojo H; Ohba S; Fukai A; Hosaka Y; Ikeda T; Saito T; Hirata M; Chikuda H; Takato T; Kawaguchi H; Chung UI
Ann Rheum Dis; 2013 May; 72(5):748-53. PubMed ID: 23041841
[TBL] [Abstract][Full Text] [Related]
10. Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis.
Li J; Wang X; Ruan G; Zhu Z; Ding C
Expert Opin Investig Drugs; 2021 Sep; 30(9):923-930. PubMed ID: 34427483
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.
Fineman MS; McAlindon TE; Lattermann C; Swearingen CJ; Kennedy S; Lopez VA; Simsek I; Tambiah JRS; Yazici Y
Rheumatol Ther; 2023 Dec; 10(6):1741-1752. PubMed ID: 37902943
[TBL] [Abstract][Full Text] [Related]
12. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.
Tambiah JRS; Kennedy S; Swearingen CJ; Simsek I; Yazici Y; Farr J; Conaghan PG
Rheumatol Ther; 2021 Jun; 8(2):973-985. PubMed ID: 34101138
[TBL] [Abstract][Full Text] [Related]
13. Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin.
Marhardt K; Muurahainen N
Drug Res (Stuttg); 2015 Nov; 65 Suppl 1():S13. PubMed ID: 26536178
[No Abstract] [Full Text] [Related]
14. Sample size calculations for detecting disease-modifying osteoarthritis drug effects on the incidence of end-stage knee osteoarthritis in clinical trials: Data from the Osteoarthritis Initiative.
Flechsenhar K; Ried JS; Driban JB; Price LL; McAlindon T
Semin Arthritis Rheum; 2019 Aug; 49(1):3-8. PubMed ID: 30611544
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate, a promising disease modifying osteoarthritis drug.
Han W; Fan S; Bai X; Ding C
Expert Opin Investig Drugs; 2017 Mar; 26(3):375-380. PubMed ID: 28092725
[TBL] [Abstract][Full Text] [Related]
16. Candidates for Intra-Articular Administration Therapeutics and Therapies of Osteoarthritis.
Toyoda E; Maehara M; Watanabe M; Sato M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808364
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for the treatment of knee osteoarthritis.
Yu SP; Hunter DJ
Expert Opin Emerg Drugs; 2015 Sep; 20(3):361-78. PubMed ID: 25865855
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of therapeutic efficacy of intra-articular oxaceprol with conventional modalities in osteoarthritis animal model.
Pawar HS; Francis NK; Hota T; Peter N; Mitra A
Clin Rheumatol; 2018 Aug; 37(8):2195-2201. PubMed ID: 29637484
[TBL] [Abstract][Full Text] [Related]
19. Canine IL4-10 fusion protein provides disease modifying activity in a canine model of OA; an exploratory study.
van Helvoort EM; Popov-Celeketic J; Eijkelkamp N; Coeleveld K; Tryfonidou MA; Wijne CD; Hack CE; Lafeber FPJG; Mastbergen SC
PLoS One; 2019; 14(7):e0219587. PubMed ID: 31295306
[TBL] [Abstract][Full Text] [Related]
20. INHIBITION OF WINGLESS-RELATED INTEGRATION SITE (WNT) SIGNALLING MAY TREAT OSTEOARTHRITIS OF THE KNEE.
Lane NE
Trans Am Clin Climatol Assoc; 2020; 131():55-64. PubMed ID: 32675843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
